Premium
Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array
Author(s) -
Jacob Francis,
Goldstein Darlene R.,
Bovin Nicolai V.,
Pochechueva Tatiana,
Spengler Marianne,
Caduff Rosemarie,
Fink Daniel,
Vuskovic Marko I.,
Huflejt Margaret E.,
HeinzelmannSchwarz Viola
Publication year - 2011
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.26002
Subject(s) - ovarian cancer , abo blood group system , glycan , antibody , antigen , biomarker , glycoprotein , cancer , glycosylation , cancer antigen , medicine , oncology , cancer research , biology , immunology , microbiology and biotechnology , biochemistry
Epithelial ovarian cancer has the highest mortality rate among gynecological cancers. Altered glycosylation is associated with oncogenic transformation producing tumor‐associated carbohydrate antigens. We investigated the potential of natural occurring antiglycan antibodies in the diagnosis of ovarian cancer by using printed glycan array. Antiglycan antibodies bound to 203 chemically synthesized printed glycans were detected via biotin‐streptavidin fluorescence system in serum of women with normal operative findings (healthy controls; n = 24) and nonmucinous borderline or ovarian cancer of various FIGO stages ( n = 33). Data were validated measuring blood group associated di‐, tri and tetrasaccharide antigens on known ABO blood groups. Antiglycan antibodies demonstrated high reproducibility ( r c > 0.9). Cluster analysis identified repetitive patterns of specific core carbohydrate structures: 11 N ‐linked glycans, 3 O ‐linked glycans and 2 glycosphingolipids. Biomarker detection revealed 24 glycans including P 1 ( Galα1–4Galβ1–4GlcNAcβ ; p < 0.001) significantly discriminating between (low‐) malignant tumors and healthy controls. Comparable sensitivity and specificity with tumor marker CA125 was achieved by a panel of multivariate selected and linear combined antiglycan antibody signals (79.2 and 84.8%, respectively). Our findings demonstrate the potential of glycan arrays in the development of a new generation of biomarkers for ovarian cancer.